Serotipos no vacunales emergentes causantes de enfermedad neumocócica invasora en la era de la vacuna 7-valente

Martínez, Felipe González; Gómez, María Luisa Navarro; Lozano, J. Saavedra; Sebastián, Marcelo; Fernández, R. Rodríguez; Sanchéz, M. González; Mansilla, Emilia Cercenado; Matos, T. Hernández-Sampelayo

doi:10.1016/j.anpedi.2013.05.003

Cited by 7 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This phenomenon has been experienced in many countries including the USA and UK, where a dramatic increase in IPD caused by non-vaccine serotypes following PCV7 introduction offset some of the benefits of vaccination [ 5 , 50 ]. Serotype replacement was particularly observed for the multi-resistant serotype 19A [ 51 – 53 ], which is only covered by PCV13. As a consequence, many Western countries replaced the earlier version of PCV7 with PCV13 in their national immunization programs due to the rapid rise of this virulent serotype in invasive pneumococcal isolates [ 54 ].…”

Section: Discussionmentioning

confidence: 99%

Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines

et al. 2015

View full text Add to dashboard Cite

ObjectivesThe objective of this study is to assess the value for money of introducing pneumococcal conjugate vaccines as part of the immunization program in a lower-middle income country, the Philippines, which is not eligible for GAVI support and lower vaccine prices. It also includes the newest clinical evidence evaluating the efficacy of PCV10, which is lacking in other previous studies.MethodsA cost-utility analysis was conducted. A Markov simulation model was constructed to examine the costs and consequences of PCV10 and PCV13 against the current scenario of no PCV vaccination for a lifetime horizon. A health system perspective was employed to explore different funding schemes, which include universal or partial vaccination coverage subsidized by the government. Results were presented as incremental cost-effectiveness ratios (ICERs) in Philippine peso (Php) per QALY gained (1 USD = 44.20 Php). Probabilistic sensitivity analysis was performed to determine the impact of parameter uncertainty.ResultsWith universal vaccination at a cost per dose of Php 624 for PCV10 and Php 700 for PCV13, both PCVs are cost-effective compared to no vaccination given the ceiling threshold of Php 120,000 per QALY gained, yielding ICERs of Php 68,182 and Php 54,510 for PCV10 and PCV13, respectively. Partial vaccination of 25% of the birth cohort resulted in significantly higher ICER values (Php 112,640 for PCV10 and Php 84,654 for PCV13) due to loss of herd protection. The budget impact analysis reveals that universal vaccination would cost Php 3.87 billion to 4.34 billion per annual, or 1.6 to 1.8 times the budget of the current national vaccination program.ConclusionThe inclusion of PCV in the national immunization program is recommended. PCV13 achieved better value for money compared to PCV10. However, the affordability and sustainability of PCV implementation over the long-term should be considered by decision makers.

show abstract